Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Explore the Innovation Trends Shaping Tomorrow’s Investment Landscape (click to learn more) Sekur Private Data Advances Defense-Grade Secure Communications Platform (click to learn more) Sorrento Resources Ltd. Intersects 33m of 2.12% TREO, Bottom Brook, Newfoundland (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Immunic Inc IMUX

Healthcare Biotechnology
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe... see more

Recent & Breaking News (NDAQ:IMUX)

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

PR Newswire November 26, 2025

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

PR Newswire November 13, 2025

Immunic to Participate in Industry and Investor Conferences in November

PR Newswire October 29, 2025

Immunic to Participate in Scientific and Investor Conferences in October

PR Newswire October 1, 2025

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

PR Newswire September 25, 2025

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

PR Newswire September 9, 2025

Immunic to Participate in Investor and Scientific Conferences in September

PR Newswire September 4, 2025

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

PR Newswire August 7, 2025

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

PR Newswire June 24, 2025

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

PR Newswire June 5, 2025

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

PR Newswire June 3, 2025

Immunic to Participate in Investor, Scientific and Industry Conferences in June

PR Newswire June 2, 2025

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

PR Newswire May 29, 2025

Immunic, Inc. Announces Proposed Public Offering

PR Newswire May 28, 2025

Immunic to Participate in Scientific and Industry Conferences in May

PR Newswire May 2, 2025

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

PR Newswire April 30, 2025

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

PR Newswire April 10, 2025

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

PR Newswire April 9, 2025

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

PR Newswire April 1, 2025

Immunic to Participate in Scientific and Investor Conferences in March

PR Newswire March 3, 2025

Podcasts